Palvella Therapeutics (PVLA) EBITDA (2016 - 2024)
Historic EBITDA for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$3.4 million.
- Palvella Therapeutics' EBITDA fell 10886.75% to -$3.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 19729.84%. This contributed to the annual value of -$17.4 million for FY2024, which is 19729.84% down from last year.
- Latest data reveals that Palvella Therapeutics reported EBITDA of -$3.4 million as of Q4 2024, which was down 10886.75% from -$7.0 million recorded in Q3 2024.
- Palvella Therapeutics' EBITDA's 5-year high stood at $38.0 million during Q4 2023, with a 5-year trough of -$16.2 million in Q3 2021.
- Moreover, its 5-year median value for EBITDA was -$7.9 million (2022), whereas its average is -$5.7 million.
- In the last 5 years, Palvella Therapeutics' EBITDA crashed by 230567.01% in 2020 and then skyrocketed by 52746.62% in 2023.
- Quarter analysis of 5 years shows Palvella Therapeutics' EBITDA stood at -$13.9 million in 2020, then soared by 33.02% to -$9.3 million in 2021, then grew by 4.71% to -$8.9 million in 2022, then skyrocketed by 527.47% to $38.0 million in 2023, then crashed by 108.87% to -$3.4 million in 2024.
- Its last three reported values are -$3.4 million in Q4 2024, -$7.0 million for Q3 2024, and -$4.4 million during Q2 2024.